<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04803461</url>
  </required_header>
  <id_info>
    <org_study_id>CLIVP</org_study_id>
    <nct_id>NCT04803461</nct_id>
  </id_info>
  <brief_title>Catecholamines Level in Vitiligo Patients Before and After Excimer Light</brief_title>
  <official_title>Catecholamines Level in Urine and Serum in Stable Non-segmental Vitiligo Patients Before and After Excimer Light</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vitiligo is an acquired cutaneous disorder of pigmentation, with a 1-2% incidence worldwide,&#xD;
      without predilection for sex or race. People affected by vitiligo have a vast reduction of&#xD;
      quality of life, caused by the color contrast between healthy pigmented skin and the&#xD;
      depigmented vitiligo patches due to death of melanocytes, which may cause psychological&#xD;
      problems to the patient.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite much research, the etiology of vitiligo and the causes of melanocyte death are not&#xD;
      clear. Conventionally, there have been three hypotheses to explain the pathogenesis of&#xD;
      vitiligo: neural, immune and self-destructive, but none can completely explain the disease&#xD;
      and are probably interrelated.&#xD;
&#xD;
      From therapeutic and prognostic viewpoint, vitiligo is broadly classified in two major&#xD;
      subtypes, segmental vitiligo (SV) including focal lesions confined to a segment of the body&#xD;
      that does not progress towards generalized disease; and non-segmental vitiligo (NSV) which&#xD;
      comprises all generalized usually symmetrical forms, including acrofacial vitiligo.&#xD;
&#xD;
      The increased release of catecholamines (CA) from the autonomic nerve endings in the&#xD;
      micro-environment of melanocytes in the affected skin areas might be involved in the&#xD;
      aetiopathogenesis of vitiligo through two main mechanisms: a direct cytotoxic action of CA&#xD;
      and/or their o-diphenol catabolites and an indirect action, skin and mucosa arterioles&#xD;
      possess receptors, activation of which by CA discharge may cause a severe vasoconstriction,&#xD;
      leading to epidermal and dermal hypoxia with excessive production of toxic oxyradicals&#xD;
      generated by different pathways.In both cases, a genetic predisposition due to insufficient&#xD;
      radical scavengers in the affected areas should be taken into account.&#xD;
&#xD;
      First line of non-surgical therapy includes topical corticosteroid therapy and phototherapy&#xD;
      (solar exposition, Psoralen + UVA (PUVA), narrowband UVB (NB-UVB). (8-10). The NB-UVB is now&#xD;
      considered as the best treatment for extensive vitiligo vulgaris due to its relatively good&#xD;
      efficacy and excellent tolerance .&#xD;
&#xD;
      Contrary to the majority of laser devices, the 308-nm excimer laser is not a ''destructive''&#xD;
      form of therapy but induces photobiological effects similar to selective UVB phototherapy&#xD;
      (311-312 nm).As for UVB phototherapy, it could be judged that the efficiency of the 308-nm&#xD;
      excimer laser in treating vitiligo depends on immunomodulatory effects (induction of the&#xD;
      secretion of cytokines, T-lymphocytes apoptosis) and stimulation of melanocyte migration and&#xD;
      proliferation from the niche located in hair follicles. The 308-nm excimer laser allows a&#xD;
      selective treatment of the lesions. This device has already shown interesting results in&#xD;
      post-resurfacing leukoderma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>serum and urinary catecholamine level in stable non segmental vitiligo patients</measure>
    <time_frame>three months</time_frame>
    <description>Lesions will be Patients will be treated by Excimer light twice weekly for a maximum of 20 sessions&#xD;
Catecholamines level will be measured in urine and serum before beginning of sessions.&#xD;
catecholamines level in urine and serum will be measured after completion of sessions.</description>
  </primary_outcome>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Vitiligo, Generalized</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>serum and urinary catecholamines</intervention_name>
    <description>estimation of level of serum and urinary catecholamines before and after excimer light treatment for patient with non segmental vitiligo.</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Urine Serum&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Our study will include 21 stable non segmental vitiligo patients subjected to excimer light&#xD;
        treatment .All patients will be recruited from the outpatient clinic of dermatology and&#xD;
        andrology department of Assiut University.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with clinically stable non-segmental vitiligo of different ages and sex&#xD;
             treated with excimer light&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant and lactating women.&#xD;
&#xD;
               -  Personal history of hypertrophic scarring, melanoma or other skin cancer.&#xD;
&#xD;
               -  Immunosuppression or taking immunosuppressive or photosensitizing drugs, and&#xD;
                  phototherapy or any other vitiligo treatment during the last 3 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Azza Mahfouz, professor</last_name>
    <phone>01001801039</phone>
    <email>azzamahfouz@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Reham Maher, Lecturer</last_name>
    <phone>01005043777</phone>
    <email>rehamaher707@yahoo.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Kent G, Al'Abadie M. Psychologic effects of vitiligo: a critical incident analysis. J Am Acad Dermatol. 1996 Dec;35(6):895-8.</citation>
    <PMID>8959947</PMID>
  </reference>
  <reference>
    <citation>Parsad D, Pandhi R, Dogra S, Kanwar AJ, Kumar B. Dermatology Life Quality Index score in vitiligo and its impact on the treatment outcome. Br J Dermatol. 2003 Feb;148(2):373-4.</citation>
    <PMID>12588405</PMID>
  </reference>
  <reference>
    <citation>Westerhof W, d'Ischia M. Vitiligo puzzle: the pieces fall in place. Pigment Cell Res. 2007 Oct;20(5):345-59. Review.</citation>
    <PMID>17850508</PMID>
  </reference>
  <reference>
    <citation>Gauthier Y, Cario Andre M, Ta√Øeb A. A critical appraisal of vitiligo etiologic theories. Is melanocyte loss a melanocytorrhagy? Pigment Cell Res. 2003 Aug;16(4):322-32. Review.</citation>
    <PMID>12859615</PMID>
  </reference>
  <reference>
    <citation>Morrone A, Picardo M, de Luca C, Terminali O, Passi S, Ippolito F. Catecholamines and vitiligo. Pigment Cell Res. 1992 Mar;5(2):65-9.</citation>
    <PMID>1321419</PMID>
  </reference>
  <reference>
    <citation>Cucchi ML, Frattini P, Santagostino G, Orecchia G. Higher plasma catecholamine and metabolite levels in the early phase of nonsegmental vitiligo. Pigment Cell Res. 2000 Feb;13(1):28-32.</citation>
    <PMID>10761993</PMID>
  </reference>
  <reference>
    <citation>Mofty ME, Zaher H, Esmat S, Youssef R, Shahin Z, Bassioni D, Enani GE. PUVA and PUVB in vitiligo--are they equally effective? Photodermatol Photoimmunol Photomed. 2001 Aug;17(4):159-63.</citation>
    <PMID>11499536</PMID>
  </reference>
  <reference>
    <citation>Scherschun L, Kim JJ, Lim HW. Narrow-band ultraviolet B is a useful and well-tolerated treatment for vitiligo. J Am Acad Dermatol. 2001 Jun;44(6):999-1003.</citation>
    <PMID>11369913</PMID>
  </reference>
  <reference>
    <citation>Taneja A. Treatment of vitiligo. J Dermatolog Treat. 2002 Mar;13(1):19-25. Review.</citation>
    <PMID>12006134</PMID>
  </reference>
  <reference>
    <citation>Friedman PM, Geronemus RG. Use of the 308-nm excimer laser for postresurfacing leukoderma. Arch Dermatol. 2001 Jun;137(6):824-5.</citation>
    <PMID>11405786</PMID>
  </reference>
  <reference>
    <citation>Ostovari N, Passeron T, Zakaria W, Fontas E, Larouy JC, Blot JF, Lacour JP, Ortonne JP. Treatment of vitiligo by 308-nm excimer laser: an evaluation of variables affecting treatment response. Lasers Surg Med. 2004;35(2):152-6.</citation>
    <PMID>15334620</PMID>
  </reference>
  <reference>
    <citation>Lilly E, Lu PD, Borovicka JH, Victorson D, Kwasny MJ, West DP, Kundu RV. Development and validation of a vitiligo-specific quality-of-life instrument (VitiQoL). J Am Acad Dermatol. 2013 Jul;69(1):e11-8. doi: 10.1016/j.jaad.2012.01.038. Epub 2012 Feb 25.</citation>
    <PMID>22365883</PMID>
  </reference>
  <reference>
    <citation>Rossiter ND, Chapman P, Haywood IA. How big is a hand? Burns. 1996 May;22(3):230-1.</citation>
    <PMID>8726264</PMID>
  </reference>
  <reference>
    <citation>Schallreuter KU, Wood JM, Lemke KR, Levenig C. Treatment of vitiligo with a topical application of pseudocatalase and calcium in combination with short-term UVB exposure: a case study on 33 patients. Dermatology. 1995;190(3):223-9.</citation>
    <PMID>7599386</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 13, 2021</study_first_submitted>
  <study_first_submitted_qc>March 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2021</study_first_posted>
  <last_update_submitted>March 16, 2021</last_update_submitted>
  <last_update_submitted_qc>March 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Marwa sayed ali</investigator_full_name>
    <investigator_title>principle investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitiligo</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

